Vol 5 (2020): Continuous Publishing
Original paper
Published online: 2020-09-18

open access

Page views 542
Article views/downloads 507
Get Citation

Connect on Social Media

Connect on Social Media

Blood cell ratios in patients with primary acquired nasolacrimal duct obstruction

Mahmut Atum1, Gürsoy Alagöz1
Ophthalmol J 2020;5:76-80.


Background: In this study, we aimed to measure neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and mean platelet volume (MPV) levels in primary acquired nasolacrimal duct obstruction (PANDO) patients and to determine whether there it could be used as a marker for PANDO. Material and methods: This retrospective study included 61 patients with PANDO and 65 healthy controls. Data were excluded from the file records of patients who underwent external dacryocystorhinostomy (DCR). Blood samples were obtained from venous blood and serum neutrophil, lymphocyte, and platelet data of all patients were recorded and also, NLR-PLR values were calculated. Results: There was no significant difference between PANDOs and controls in terms of gender and age (p > 0.05). Neutrophil-to-lymphocyte was significantly increased in PANDOs compared to the controls (p < 0.05). There was no statistically significant difference between PANDOs and controls in term of PLR (p > 0.05). The average MPV in the PANDOs was found to be significantly lower than controls (p < 0.05). Conclusion: Neutrophil-to-lymphocyte ratio and MPV counts were associated with PANDO.

Article available in PDF format

View PDF Download PDF file


  1. Bartley G. Acquired Lacrimal Drainage Obstruction. Ophthal Plast Reconstr Surg. 1993; 9(1): 11–26.
  2. Busse H, Müller KM. [Development of idiopathic dacryostenosis (clinical and pathologico-anatomical findings)]. Klin Monbl Augenheilkd. 1977; 170(4): 627–632.
  3. Linberg JV, McCormick SA. Primary acquired nasolacrimal duct obstruction. A clinicopathologic report and biopsy technique. Ophthalmology. 1986; 93(8): 1055–1063.
  4. Mauriello JA, Palydowycz S, DeLuca J. Clinicopathologic study of lacrimal sac and nasal mucosa in 44 patients with complete acquired nasolacrimal duct obstruction. Ophthalmic Plast Reconstr Surg. 1992; 8(1): 13–21.
  5. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008; 102(6): 653–657.
  6. Akdag S, Akyol A, Asker M, et al. Platelet-to-Lymphocyte Ratio May Predict the Severity of Calcific Aortic Stenosis. Med Sci Monit. 2015; 21: 3395–3400.
  7. Akboga MK, Canpolat U, Yuksel M, et al. Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: A single center large-scale study. Platelets. 2016; 27(2): 178–183.
  8. Tsiara S, Elisaf M, Jagroop IA, et al. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost. 2003; 9(3): 177–190.
  9. Azab B, Daoud J, Naeem FB, et al. Neutrophil-to-lymphocyte ratio as a predictor of worsening renal function in diabetic patients (3-year follow-up study). Ren Fail. 2012; 34(5): 571–576.
  10. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012; 34(3): 326–334.
  11. Ryu HJ, Seo MiR, Choi HJ, et al. Mean platelet volume as a marker for differentiating disease flare from infection in Behçet's disease. Int J Rheum Dis. 2018; 21(8): 1640–1645.
  12. Yayla Ç, Açikgöz SK, Yayla KG, et al. The association between platelet-to-lymphocyte ratio and inflammatory markers with the severity of aortic stenosis. Biomark Med. 2016; 10(4): 367–373.
  13. Racz JM, Cleghorn MC, Jimenez MC, et al. Predictive Ability of Blood Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2015; 22(7): 2343–2350.
  14. Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. Clinics (Sao Paulo). 2015; 70(7): 524–530.
  15. Alan S, Tuna S, Türkoğlu EB. The relation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behçet's syndrome. Kaohsiung J Med Sci. 2015; 31(12): 626–631.
  16. Mercan R, Bitik B, Tufan A, et al. The Association Between Neutrophil/Lymphocyte Ratio and Disease Activity in Rheumatoid Arthritis and Ankylosing Spondylitis. J Clin Lab Anal. 2016; 30(5): 597–601.
  17. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001; 102(1): 5–14.
  18. Koseoglu HI, Altunkas F, Kanbay A, et al. Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis. 2015; 39(2): 179–185.
  19. Unal D, Eroglu C, Kurtul N, et al. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 2013; 14(9): 5237–5242.
  20. Akkaya E, Gul M, Ugur M. Platelet to lymphocyte ratio: a simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol. 2014; 177(2): 597–598.
  21. Akboga MK, Canpolat U, Yayla C, et al. Association of Platelet to Lymphocyte Ratio With Inflammation and Severity of Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease. Angiology. 2016; 67(1): 89–95.
  22. Lian L, Xia YY, Zhou C, et al. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer. Cancer Biomark. 2015; 15(6): 899–907.
  23. Sunbul M, Gerin F, Durmus E, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clin Exp Hypertens. 2014; 36(4): 217–221.
  24. Inagaki N, Kibata K, Tamaki T, et al. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2014; 83(1): 97–101.
  25. Kisacik B, Tufan A, Kalyoncu U, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75(3): 291–294.
  26. Bowman SJ. Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol. 2002; 31(5): 251–259.
  27. Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica. 1997; 82(3): 375–381.
  28. Bath P, Algert C, Chapman N, et al. PROGRESS Collaborative Group. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996; 7(2): 157–161.
  29. Bath P, Algert C, Chapman N, et al. PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004; 35(3): 622–626.
  30. Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002; 117(2): 399–404.
  31. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001; 96(3): 776–781.